A study to investigate the mass balance, absolute bioavailability (BA), pharmacokinetics (PK), and metabolism of a single oral dose 60 mg [14C]-alogabat and an IV microdose of 100 μg [13C]-alogabat

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506044-16-00

Acronym

BP41817

Enrollment

Registered

2023-10-26

Start date

2023-12-14

Completion date

2024-03-15

Last updated

2023-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not applicable (NA), There is no medical condition being investigated.

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026